Extracellular vesicle-based drug delivery systems for head and neck squamous cell carcinoma: A systematic review
K Dżaman, K Czerwaty - Pharmaceutics, 2023 - mdpi.com
It is estimated that there are over 890,000 new cases of head and neck squamous cell
carcinoma (HNSCC) worldwide each year, accounting for approximately 5% of all cancer …
carcinoma (HNSCC) worldwide each year, accounting for approximately 5% of all cancer …
[HTML][HTML] Ophthalmologic toxicities of antineoplastic agents in genitourinary cancers: Mechanisms, management, and clinical implications
A Mahadevan, O Yazdanpanah, V Patel… - Current Problems in …, 2025 - Elsevier
Genitourinary cancers affect over 480,000 patients in the United States annually. While
promising therapeutic modalities continue to emerge, notably immune checkpoint inhibitors …
promising therapeutic modalities continue to emerge, notably immune checkpoint inhibitors …
Preclinical Efficacy of Cabazitaxel Loaded Poly (2-alkyl cyanoacrylate) Nanoparticle Variants
R Valsalakumari, AD Pandya… - International Journal …, 2024 - Taylor & Francis
Background Biodegradable poly (alkyl cyanoacrylate)(PACA) nanoparticles (NPs) are
receiving increasing attention in anti-cancer nanomedicine development not only for …
receiving increasing attention in anti-cancer nanomedicine development not only for …
[HTML][HTML] Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple …
P Meyer-Wilmes, J Huober, M Untch, JU Blohmer… - ESMO open, 2024 - Elsevier
Background The GENEVIEVE study, comparing neoadjuvant cabazitaxel versus paclitaxel
in triple-negative breast cancer (TNBC) and luminal B/human epidermal growth factor …
in triple-negative breast cancer (TNBC) and luminal B/human epidermal growth factor …
Patologías ungueales inducidas por el tratamiento quimioterápico con taxanos en mujeres con cáncer de mama. Un estudio experimental mediante fuentes …
A Pérerz Hernández - dspace.umh.es
Introducción: El cáncer de mama es una de las principales causas de muerte entre las
mujeres de España. Como tratamientos eficaces antes y después de la cirugía tenemos a …
mujeres de España. Como tratamientos eficaces antes y después de la cirugía tenemos a …